The first medicine to treat tumors with a specific mutation receives conditional approval from the European Medicines Agency’s (EMA) human medicines committee (CHMP). The medication promises to work on the tumor irrespective of the tumor's area of origin.
As per the EMA, a medication named as Bayer's Vitrakvi treats both adult and pediatric patients having solid tumors with Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. The medications treat patients, who have their tumors spread invasively and cannot be surgically removed. The Vitrakvi's safety measures were evaluated in three single-arm trials with a total of 102 adults and children having different forms of cancer.